PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 864-870

  Young, Guy ^a   Auerswald, Guenter ^b   Jimenez Yuste, Victor ^c   Lambert, Thierry ^d   Morfini, Massimo ^e   Santagostino, Elena ^f   Blanchette, Victor ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Prof Hess Children's Hospital   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hemophilia; inhibitors; prophylaxis; recombinant factor VIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CHILD; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HEALTH CARE UTILIZATION; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA PATIENTS WITH INHIBITOR; HOSPITALIZED CHILD; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; MIDDLE AGED; OBSERVATION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84870245946     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.08.305     Document Type: Article

References (20)

1. I.M. Nilsson, E. Berntorp, T. Löfqvist, and H. Pettersson Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B J Intern Med 232 1992 25 32
2. M.J. Manco-Johnson, T.C. Abshire, A.D. Shapiro, B. Riske, M.R. Hacker, and R. Kilcoyne Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia N Engl J Med 357 2007 535 544
3. P. Collins, A. Faradji, M. Morfini, M.M. Enriquez, and L. Schwartz Efficacy and safety of secondary prophylactic vs. on-demand sucrose formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study J Thromb Haemost 8 2010 83 89
4. M.W. Hilgartner, A. Makipernaa, and D.M. Dimichele Long-term FEIBA prophylaxis does not prevent progression of existing joint disease Hemophilia 9 2003 261 268
5. B. Siegmund, H. Richter, and H. Pollmann Prophylactic treatment with FEIBA of a hemophilia A patient with inhibitor: what are the costs, what are the benefits? Hemophilia 11 2005 638 641
6. D. Dimichele, and C. Négrier A retrospective postlicensure survey of FEIBA efficacy and safety Hemophilia 12 2006 352 362
7. S. Ohga, A. Nomura, H. Takada, N. Suga, and T. Hara Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor Am J Hematol 82 2007 145 149
8. C.A. Leissinger, D.L. Becton, N.P. Ewing, and L.A. Valentino Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with hemophilia A and inhibitors Hemophilia 13 2007 249 255
9. V. Jiménez-Yuste, M.T. Alvarez, M. Martín-Salces, M. Quintana, C. Rodriguez-Merchan, and C. Lopez-Cabarcos Prophylaxis in 10 patients with severe hemophilia A and inhibitor: different approaches for different clinical situations Hemophilia 15 2009 203 209
10. L.A. Valentino The benefits of prophylactic treatment with APCC in patients with hemophilia and high-titre inhibitors: a retrospective case series Hemophilia 15 2009 733 742
11. H.A. Cooper, C.P. Jones, E. Campion, H.R. Roberts, and U. Hedner Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopaedic procedures Hemophilia 7 2001 517 522
12. H.H. Brackmann, E. Effenberger, L. Hess, R. Schwaab, and J. Oldenburg NovoSeven in immune tolerance therapy Blood Coagul Fibrinolysis 11 Suppl. 1 2000 S39 S44
13. B.R. Saxon, D. Shanks, C.B. Jory, and V. Williams Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint Thromb Haemost 86 2001 1126 1127
14. G. Young, M. McDaniel, and D.J. Nugent Prophylactic recombinant factor VIIa in hemophilia patients with inhibitors Hemophilia 11 2005 203 207
15. M. Morfini, G. Auerswald, R.A. Kobelt, G.F. Rivolta, J. Rodriguez-Martorell, and F.A. Scaraggi Prophylactic treatment of hemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Hemophilia Centres Hemophilia 13 5 2007 Sep 502 507
16. V. Jimenez-Yuste, M. Quintana, M.T. Alvarez, M. Martin-Salces, and F. Hernandez-Navarro "Primary prophylaxis" with rFVIIa in a patient with severe hemophilia A and inhibitor Blood Coagul Fibrinolysis 19 2008 719 720
17. C. Sedano, C. Altisent, F. Garcia-Candel, F. Gimenez, E. Mingot, and R. Nunez Retrospective Evaluation of Secondary Episodic Prophylaxis with rFVIIa in Hemophilia Patients with Inhibitor J Coagul Disord 2 2010 5 9
18. B.A. Konkle, L.S. Ebbesen, E. Erhardtsen, R.P. Bianco, T. Lissitchkov, and L. Rusen Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors J Thromb Haemost 5 2007 1904 1913
19. C. Leissinger, A. Gringeri, B. Antmen, E. Berntorp, C. Biasoli, and S. Carpenter Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors N Eng J Med 365 2011 1684 1692
20. G. Young, A.D. Shapiro, C.E. Walsh, R.A. Gruppo, R.Z. Gut, and D.L. Cooper Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) Haemophilia 18 2012 392 399